Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference
Rhea-AI Summary
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. The company's President and CEO, Joe Oliveto, will be featured in a Fireside Chat presentation on August 6th at 8 AM EDT.
Investors and interested parties can access the presentation live or as a replay for approximately 90 days after the event. The webcast will be available in the News & Events section of Milestone's corporate website at www.milestonepharma.com. This conference provides an opportunity for Milestone Pharmaceuticals to showcase its latest developments and engage with the investment community in the biotechnology sector.
Positive
- None.
Negative
- None.
News Market Reaction – MIST
In the trading session that priced this news, MIST declined 2.04%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the BTIG Virtual Biotechnology Conference, to take place from August 5-6, 2024.
The presentation will be in the form of a Fireside Chat to take place on August 6th at 8 AM EDT. The webcast will be available to watch both live and as a replay for approximately 90 days following the presentation in the News & Events section of Milestone's corporate website: www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kim Fox, Vice President, Communications, kfox@milestonepharma.com
Investor Relations
Chris Calabrese, ccalabrese@lifesciadvisors.com
Kevin Gardner, kgardner@lifesciadvisors.com
